Oral toxicity evaluation of probiotic strains isolated from Finger millet [Eleusine coracana (L.) Gaertn.] in Wistar rat models (in vivo)

Divisekera Mudiyanselage Wasundara Devanmini Divisekera*, Jayanetthi Koralalage Ramani Radhika Samarasekera, Chamari Hettiarachchi, Rukesh Maharjan, Jaanaki Gooneratne, Muhammed Iqbal Choudhary, Subramaniam Gopalakrishnan, Atia-ul Wahab and Saikat Datta Mazumdar

*Industrial Technology Institute, 363, Baddchaloka Mawatha, Colombo 07, Sri Lanka
1University of Colombo,94, Kumarakuthunga Munidasu Mawatha, Colombo 07, Sri Lanka
2H. E. J. Research Institute of Chemistry, International Centre for Chemical and Biological Sciences, University of Karachi, University of Karachi, Karachi City, Sindh 75270, Pakistan
3Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi City, Sindh 75270, Pakistan
4International Crops Research Institute for the Semi-Arid Tropics, Patancheru, Hyderabad, Telangana 502324, India

Article info
Received 14 August 2021
Revised 27 August 2021
Accepted 31 August 2021
Published online 30 September 2021

Regular article

Keywords:
Finger-millet; Oral toxicity; Probiotics; Wistar rats

Abstract
This study evaluates the oral toxicity of five probiotic strains recently isolated from fermented flour of finger-millet (Eleusine coracana) varieties of Sri Lanka. Probiotic strains; Lactobacillus plantarum MF405176, Lactobacillus fermentum MF033346, Enterococcus faecalis subsp. lactis MF480428, Enterococcus faecium MF480431 and Lactococcus lactis MF480434 were evaluated for acute and sub-chronic oral toxicity in Wistars. Three individual doses (10^8CFU/g, 10^9CFU/g and 10^10CFU/g) of each probiotic strain at single oral dose of 5000 mg/kg bw were orally administered to rats and observations were done till 14th day. Since no animals demonstrated signs of toxicity as a result of the administrated probiotic strains, repeated dose sub-chronic oral toxicity study was conducted by oral administration of three doses (10^8 CFU/g, 10^9 CFU/g, 10^10 CFU/g) of each probiotic strain at 1000 mg/kg bw/day for consecutive 90 days. Administration of probiotic strains to rats did not caused mortality in any of the tested doses. No changes in animal behavior, feed or water intake and negative effects on body weight observed. Probiotic feeding did not cause changes in analyzed biochemical and hematological parameters attributed to toxicity. Bacteremia, bacterial translocation and histopathological changes in rat organs were not observed. No significant difference in liver enzymes observed in treatment groups compared to control. In conclusion, all tested probiotic strains are nonpathogenic therefore could be considered as safe for human consumption.

1. Introduction
Probiotics are live microorganisms, when administrated in adequate amounts confer health benefits to the host (FAO/WHO, 2002). Probiotic bacteria consist of several genera of lactic acid bacteria (LAB) that are Gram-positive, non-spore forming, anaerobic or facultative aerobic cocci or rods producing lactic acid during carbohydrate metabolism (Fenster et al, 2019; Quinto et al, 2014). Among LAB, Lactobacillus is the largest genus and Generally Recognized as Safe (GRAS). Applications of the selected strains of Genus Enterococcus as probiotics are also well documented. Probiotics are broadly classified under functional food, therefore extend its role beyond providing adequate nutrients to improving health and preventing the risk of diseases including certain non-communicable diseases (NCD) such as cancer, hypertension, hypercholesterolemia, etc. Ability of probiotics to modulate physiological functions resulting in prevention of diseases is widely reported (Kumar et al, 2015). Beneficial effects of probiotics as antimicrobial agents against pathogenic, carcinogenic and conditionally pathogenic microorganisms are strain-specific. Antimicrobial activity involves competitive exclusion via competition for adhesion sites, competition for substrates and limiting resources, synthesis of anti-microbial substances and inhibition of toxin expression in pathogens (Denkova et al, 2017). Role of probiotics in cancer therapy may also be strain dependent and associated with their immunomodulatory effects and expression of different genes involved in cell transformation, migration and invasion (Motevaseli et al, 2017). Anti-oxidant properties of probiotics are caused by metal ion chelating ability, presence of anti-oxidant enzyme system, production of anti-oxidant metabolites, regulation of anti-oxidant signaling pathways, and regulation of enzymes producing Reactive Oxygen Species and modulating the
gut microbiota (Wang et al., 2017). Understanding reduction of lipid and cholesterol levels in human subjects by probiotics that occur through bile salt hydrolase activity and cholesterol assimilation ability has received wide attention in recent years (Duchesneau et al., 2014). Due to absence of side effects compared to drugs, probiotics are becoming an effective alternative in managing pretermen for human health (Gionchetti et al., 2007; Tripathi et al., 2014). In addition, they find application in technological advancement in food processing such as ripening, shelf-life improvement and aroma development.

Consequently, a number of new bacterial strains are being identified as probiotics and incorporated into the food and pharmaceutical formulations globally. However, assessing safety of a new probiotic strain intended to be incorporated in to food or supplement, is crucial (Conway, 1996). In this study, five new probiotic strains; Lactobacillus plantarum MF405176, Lactobacillus fermentum MF033346, Lactococcus lactis subspecies lactis MF480428, Enterococcus faecium MF480431 and Pediococcus acidilactici MF480434, previously isolated from fermented flour of finger-millet (Eleusine coracana) varieties cultivated in Sri Lanka (Divisekera et al., 2019), were investigated for oral toxicity. Probiotic strains under study exhibited preliminary requirements of survival in simulated conditions of the human gut, could aggregate and adhere to intestinal cells, free from virulence causing enzymes responsible for hemolysis, DNAs and gelatin hydrolysis and demonstrated antibiotic susceptibility (Divisekera et al., 2019). Further, these strains have already demonstrated efficacy (anti-bacterial, anti-cancer, anti-oxidant and cholesterol assimilation) in-vitro. The study envisioned to authenticate the safety (acute and sub-chronic oral toxicity) of five potential probiotic strains to establish their suitability as future probiotics.

2. Material and methods

Probiotic strains

Five probiotic strains; Lactobacillus plantarum MF405176, Lactobacillus fermentum MF033346, Lactococcus lactis subspecies lactis MF480428, Enterococcus faecium MF480431 and Pediococcus acidilactici MF480434 isolated from fermented flour of finger-millet (Eleusine coracana) varieties of Sri Lanka were selected for the study.

2.1 Oral toxicity evaluation of probiotic strains in Wistar rats

Experimental animals and housing conditions

Pathogen free Wistar rats of both sexes (aged 4-6 weeks, male and female) bred at the animal breeding unit of the ICCBS, University of Karachi, Pakistan. The animals were acclimated for one week before starting experiment. Animals were housed in stainless-steel cages (5 per cage, segregated by gender) with 12 h light/ dark cycle (8:30 am to 8:30 pm) in a controlled atmosphere (temperature 24 ± 2 °C, humidity 55 ± 2%). Animals were given access to standard rat diet (LabDiet®) and potable tap water ad libitum. Animal cage bedding was changed weekly. The study has been approved by the institutional animal care and user committee of the International Centre for Chemical and Biological Sciences (ICCBS), University of Karachi, Pakistan (Ethical clearance certificate number is 2016-0001). The study was conducted according to the ARRIVE guidelines (Sert et al., 2020) and is in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines.

Single dose acute oral toxicity study

Wistar rats were randomly divided into sixteen groups (fifteen treatment groups and one control group for each test probiotic, three treatment groups were assigned (each group receiving three doses of each probiotic, similarly three groups received three doses of each test probiotic). Likewise, for the five test probiotics under study, fifteen treatment groups were assigned. Each group consisted of 5 male and 5 female rats housed based on their gender. Body weights at randomization were 200-220 g for males, and 200-215 g for females. There doses: 10⁰ CFU/g, 10¹ CFU/g and 10¹² CFU/g of each probiotic candidates were prepared by inoculating in to 1% skim milk, stored in ice prior to administration (Zhou et al., 2000). A single oral dose of 5000 mg/kg bw of each test article (three different doses of five probiotic strains) was orally administered to treatment groups, while control group was administrated with 1% (w/v) skim milk only. During the experiment, animals' health, behaviors, mortality (if any) were observed daily for consecutive 14 days using a three-scale method; lazy, weak and sleepy-1, intermediate movements and interactions with each other-2 and active movements and interactions with each other-3. Observations including changes in feed and water intake, sleeping pattern, skin and fur, eyes and mucus membranes, respiratory, somatomotor activity, behavior pattern, breathing, tremors, convulsions, salivation, diarrhea, sleep and changes in gait and posture were recorded daily from 1st to 15th day, using three scales; * (normal), ++ (intermediate), +++ (severe). On the 15th day, live weights of all the animals were recorded. Katamine 30 mg/kg combined with medetomidine 1 mg/kg was used as the anesthetic drug and doses were calculated based on the body weights of animals, and administered intra-muscularly. Surgery was performed in accordance to guidelines given in the animal care and use course derived by The American Association for Laboratory Animal Science of the ICCBS, University of Karachi, Pakistan. Animals were observed for perception of pain prior to perform non survival surgical procedure. Surgical areas were cleaned with 70% ethanol (v/v), incision sites were clipped. Animal hearts were punctured using sterile needles and blood was drawn. From each animal, 2 ml of blood was collected to individual vacutainers containing EDTA and 4 ml of blood was collected to vacutainers containing clot activator with gel. The vacutainers were stored at 4 ± 1 °C until analyzed Animal organs portions (kidney, liver and intestine) were excised aseptically washed with sterile 10% PBS and preserved in 10% v/v formaldehyde solution. Rats were euthanized in a CO₂ chamber. Animal blood was tested for hematology, total protein, total bilirubin, total cholesterol, triglycerides, and liver function tests (total bilirubin, direct bilirubin, Alkaline phosphatase, gamma-glutamyl transferase and alanine transaminase (ALT) and lipid profile (cholesterol, triglycerides, high density lipoproteins, low density lipoproteins and very low-density lipoproteins). Histopathological examination of rat organs was performed. Bacterial translocation in blood was investigated by streaking a loop full of each blood sample on individual sterile de Man Rogosa and Sharpe (MRS) agar plates in triplicate. Bacterial translocations in organs were investigated by culturing 1 g of tissues of animal organs; liver, intestine, mesenteric lymph node and kidney on individual MRS agar plates in triplicate. MRS agar plates containing blood and organs were incubated at 37 ± 1°C for 48 h.
Repeted dose sub chronic oral toxicity study

Wistar rats were randomly divided into sixteen groups (fifteen treatment groups and one control group). For each test probiotic, three treatment groups were assigned (each group receiving different dose of test probiotic, similarly three groups received three doses of each test probiotic). Likewise, for the five test probiotics under study, fifteen treatment groups were assigned. Each group consisted of 10 male and 10 female rats. Body weights at randomization were 210-225 g for males, and 200-215 g for females.

Doses of 10^8 CFU/g, 10^10 CFU/g, 10^12 CFU/g at 1000 mg/kgbw/day was administrated orally for consecutively 90 days. Body weights of animals were measured weekly. During the experiment, animals’ health, behaviors, mortality (if any) was observed daily. Observations including changes in feed and water intake, sleeping pattern, skin and fur, eyes and mucus membranes, respiratory, somatomotor activity, behavior pattern, breathing, tremors, convulsions, salivation, diarrhea, gait and posture was also recorded weekly. Anesthesia and surgery was performed on 91st day as described in acute oral toxicity study. Prior to surgery, animals were fasted for 16 h. Surgery was performed in accordance to guidelines given in the animal care and use course derived by The American Association for Laboratory Animal Science of the ICCBS, University of Karachi, Pakistan. Hematology and biochemistry of rat blood was evaluated as per the parameters mentioned in acute oral toxicity study. Histopathological examination of rat organs including tests and control was performed. Bacterial translocation in blood and organs of rats was studies using MRS agar as mentioned under the methodology of acute oral toxicity study.

2.2 Statistical analysis

The mean and standard error of the data obtained from parallel experiments were calculated using Minitab 14. One-way ANOVA (unstacked) followed by the multiple comparisons using Tukey’s family error rate was performed to analyze the data. Values P < 0.05 were considered as significant.

3. Results

3.1 Evaluation of single dose acute oral toxicity of probiotic candidates

During the acute toxicity study, oral administration of the three doses; 10^8 CFU/g, 10^10 CFU/g, 10^12 CFU/g of probiotic strains *Lactobacillus plantarum* MF405176, *Lactobacillus fermentum* MF033346, *Lactococcus lactis* subspecies lactis MF480428, *Enterococcus faecium* MF405176 and *Pediciococcus acidilactici* MF480434 did not cause abnormal changes in sleeping pattern, skin and fur, eyes and mucus membranes, respiratory, somatomotor activity, behavior, breathing, tremors, convulsions, salivation, diarrhea, gait and posture. Furthermore, no treatment-related illness or animal death was shown. Intake of probiotics, at administrated doses, did not interrupt the usual pattern of feed and water intake in both male and female rats, neither did it cause significant difference in body weight evolution between experimental and control groups.

Results of hematological analysis of whole blood revealed significant differences (P < 0.05) in hemoglobin content in both male and female animals orally received *L plantarum* MF405176 and *L fermentation* MF033346. While others did not demonstrate significant difference. While significant differences (P < 0.05) in platelet count was observed in all female animals fed with tested probiotic strains, *L. plantarum* MF405176, *L. fermentum* MF033346, *L. lactis* subspecies lactis MF480428, *E. faecium* MF480431 and *P. acidilactici* MF480434 (Table 1). Lipid profile and liver function tests of both male and female rats received test probiotic strains revealed no significant difference (Tables 2, 3). No abnormal histopathological observations in animal organs (kidney, liver and intestine) were detected. In all experimental groups, neither bacteremia in blood nor bacterial translocation in organs observed.

3.2 Repeated dose sub chronic oral toxicity evaluation of probiotic strains

In the repeated dose sub-chronic oral toxicity study, oral administration of tested doses; 10^8 CFU/g, 10^10 CFU/g, 10^12 CFU/g of probiotic strains did not cause abnormal changes in sleeping pattern, skin and fur, eyes and mucous membranes, respiratory, somatomotor activity, behavior, breathing, tremors, convulsions, salivation, diarrhea, gait and posture in both male and female rats. Further, no treatment-related illness or animal deaths were beenfall. Oral intake of probiotics did not interrupt the usual pattern of feed and water intake in both male and female rats. Significant increment (P < 0.05) in mean body weights was observed at the end of feeding (90th day) compared to day 01 (Table 4).

With regard to the hemoglobin content, male rats, except animals administrated with *L. lactis* subspecies lactis MF480428 and *E. faecium* MF480431 and female rats, except animals administrated with *L. lactis* subspecies lactis MF480428, others demonstrated significant difference (P < 0.05) (Table 5). With regard to the RBC content, all animals both male and female except females orally administrated with *L. plantarum* MF405176, *L. fermentum* MF033346, *L. lactis* subspecies lactis MF480428 demonstrated significant difference (P < 0.05) (Table 5). With regard to the HCT/PCV, MCV and MCH content, all male and female animals except males administrated with *L. lactis* subspecies lactis MF480428 demonstrated significant difference (P < 0.05) (Table 5). Significant difference (P < 0.05) in WBC content was observed in males administrated with *E. faecium* MF480431 and females administrated with *E. faecium* MF480431 and *L. lactis* subspecies lactis MF480428 (Table 5). Significant difference (P < 0.05) in platelet content was observed in all animals except females administrated with *P. acidilactici* MF480434 (Table 5).

With regard to the lipid profile, all animals except males administrated with *L. lactis* subspecies lactis MF480428, *E. faecium* MF480431 and *P. acidilactici* MF480434 and females administrated with *L. lactis* subspecies lactis MF480428, others demonstrated significant difference (P < 0.05) in cholesterol content (Table 6). Except males administrated with *P. acidilactici* MF480434, others demonstrated significant difference (P < 0.05) in triglyceride content. All animals except females administrated with *L. fermentum* MF033346, others demonstrated significant difference (P < 0.05) in HDL and LDL content (Table 6). Significant difference in VLDL content was observed in all animals except males administrated with *E. faecium* MF480431 (Table 6).

With regard to the liver function tests, all animals demonstrated significant difference (P < 0.05) in SGPT and alkaline phosphatase (Table 7). While no significant difference in Gamma GT was observed in any of the treated animals compared to control. Except males administrated with *E. faecium* MF480431 and *P. acidilactici* MF480434, and females administrated with *L. plantarum* MF405176, *L. fermentum* MF033346, *E. faecium* MF480431 and *P. acidilactici* MF480434 others demonstrated significant difference (P < 0.05) in total bilirubin content. All animals except males administrated with *L. plantarum* MF405176 and females administrated with *L. plantarum* MF405176, *L. fermentum* MF033346, *E. faecium* MF480431 demonstrated significant difference (P < 0.05) in direct bilirubin (Table 7).
In the sub-chronic toxicity study, none of the experimental groups administered with different doses of test probiotic strains demonstrated necrosis, fibrosis, loss of normal architecture, atrophy or inflammation in any of the examined organs i.e., kidney, liver, intestine in both male and female rats indicating no histopathological abnormalities were caused by oral administered probiotics under study. None of the animals exhibited bacteremia in blood and/or demonstrate bacterial translocation in organs.

### Table 1 Hematology of rat blood in acute oral toxicity study

| Probiotic Candidate | Dos e | Hematological Parameters |
|---------------------|-------|-------------------------|
|                     |       | Hb (g/dl) | RBC (Million/µl) | HCT/PCV (%) | MCV (fl) | MCH (pg) | WBC (×10^3/l) | Platelet (×10^3/l) |
|                     | Contr ol(M) | a | b | c | d | a | b | c | a | b | c | a | b | c | a | b | c | a | b | c | a | b | c | a | b | c | a | b | c |
| L.plantarum          | D1    | 9.60 ± 0.00 | 5.09 ± 0.50 | 29.80 ± 0.00 | 58.50 ± 0.00 | 19.03 ± 0.08 | 3.87 ± 0.03 | 59.33 ± 0.33 |
| MF405176             | D2    |             |             |             |             |             |             |             |
|                     | D3    |             |             |             |             |             |             |             |
| L.fermentum          | D1    | 10.93 ± 1.10 | 5.85 ± 0.72 | 31.00 ± 3.80 | 57.70 ± 0.90 | 19.80 ± 0.30 | 3.73 ± 0.07 | 66.20 ± 17.0 |
| MF033346             | D2    | 12.37 ± 0.52 | 6.84 ± 0.13 | 30.10 ± 0.90 | 57.17 ± 2.09 | 18.57 ± 0.72 | 3.40 ± 0.10 | 90.10 ± 91.0 |
|                      | D3    | 12.60 ± 0.23 | 6.67 ± 0.08 | 30.53 ± 0.87 | 58.79 ± 0.95 | 19.80 ± 0.54 | 3.33 ± 2.64 | 95.77 ± 63.2 |
| Lactis subst. Lacticis | D1    | 11.70 ± 0.00 | 6.11 ± 0.00 | 27.30 ± 0.00 | 57.80 ± 0.00 | 19.07 ± 0.03 | 3.79 ± 0.05 | 1211 ± 100.0 |
| MF480428             | D2    | 12.60 ± 1.00 | 6.71 ± 0.21 | 27.30 ± 0.00 | 58.00 ± 0.10 | 18.94 ± 0.17 | 3.27 ± 0.27 | 9560 ± 35.0 |
|                      | D3    | 13.20 ± 0.29 | 6.00 ± 0.09 | 27.00 ± 0.20 | 58.70 ± 0.76 | 18.90 ± 0.10 | 3.18 ± 0.87 | 1050 ± 176 |
| E.faecium            | D1    | 11.40 ± 0.00 | 6.13 ± 0.00 | 34.60 ± 0.00 | 56.40 ± 0.00 | 18.73 ± 0.13 | 3.47 ± 0.03 | 11347 ± 333.0 |
| MF480431             | D2    | 12.57 ± 0.01 | 6.44 ± 0.38 | 30.63 ± 2.71 | 58.07 ± 0.93 | 18.87 ± 0.31 | 3.90 ± 1.67 | 7939 ± 86.3 |
|                      | D3    | 12.23 ± 0.13 | 6.62 ± 0.39 | 30.77 ± 0.87 | 58.77 ± 2.03 | 18.57 ± 0.83 | 3.77 ± 0.03 | 10107 ± 14.3 |
| P.acidilactici       | D1    | 12.00 ± 0.34 | 5.83 ± 0.15 | 30.27 ± 0.57 | 60.60 ± 0.70 | 20.60 ± 0.40 | 3.60 ± 0.91 | 8683 ± 58.3 |
| MF480434             | D2    | 11.50 ± 0.17 | 6.46 ± 0.09 | 30.63 ± 0.92 | 59.77 ± 0.99 | 19.57 ± 0.29 | 2.10 ± 0.31 | 956 ± 12.9 |
|                      | D3    | 11.47 ± 0.17 | 6.68 ± 0.34 | 30.40 ± 1.23 | 56.00 ± 1.00 | 17.00 ± 0.50 | 3.73 ± 0.63 | 10707 ± 90.3 |
| E. faecium           | D1    | 11.37 ± 0.26 | 6.52 ± 0.14 | 30.27 ± 0.83 | 57.20 ± 0.15 | 19.80 ± 0.21 | 6.17 ± 2.09 | 1080 ± 146.0 |
| MF480431             | D2    | 11.87 ± 0.13 | 6.96 ± 0.22 | 30.27 ± 1.63 | 56.93 ± 0.79 | 18.50 ± 0.40 | 5.20 ± 2.45 | 8923 ± 76.7 |
|                      | D3    | 12.07 ± 0.03 | 6.09 ± 0.22 | 31.83 ± 0.27 | 58.20 ± 2.04 | 18.33 ± 0.53 | 5.43 ± 1.73 | 8983 ± 58.4 |
| Lactis subst. Lacticis | D1    | 9.40 ± 0.00 | 5.39 ± 0.30 | 30.20 ± 0.60 | 58.10 ± 0.56 | 18.60 ± 0.30 | 3.30 ± 0.05 | 589.67 ± 133.0 |
| MF480428             | D2    |             |             |             |             |             |             |             |
|                      | D3    |             |             |             |             |             |             |             |

Data is expressed as mean ± SEM, n=5. Within a column containing three doses of each probiotic candidate compared to control, mean values superscripted with different letters are significantly different (p < 0.05). (D1) Dose: 1 x 10^8 CFU/ml, (D2) Dose: 2 x 10^9 CFU/ml, (D3) Dose: 3 x 10^10 CFU/ml.

Male (M), Female (F), Hemoglobin (Hb), Erythrocyte count (RBC), Hematocrit/Packed Cell Volume (HCT/PCV), Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin (MCH) and Total leukocyte count (WBC).


| Probiotic candidates | Dose   | Control /Sex | Lipid profile parameters |
|----------------------|--------|--------------|--------------------------|
|                      |        |              | Cholesterol (mg/dl)       |
|                      |        |              | Triglycerides (mg/dl)     |
|                      |        |              | HDL (mg/dl)               |
|                      |        |              | LDL (mg/dl)               |
|                      |        |              | VLDL (mg/dl)              |
|                      |        | Control (M)  | 57.67 ± 2.67<sup>a</sup> |
|                      |        | 48.33 ± 1.33<sup>a</sup> | 47.00 ± 1.15<sup>a</sup> | 10.00 ± 1.00<sup>a</sup> | 9.57 ± 0.12<sup>a</sup> |
| *L. plantarum* MF405176 | D1     | M            | 63.70 ± 14.8<sup>a</sup>  |
|                      | D2     |              | 51.00 ± 3.06<sup>a</sup>  |
|                      | D3     |              | 48.33 ± 6.90<sup>a</sup>  |
| *L. fermentum* MF033346 | D1     | M            | 67.67 ± 1.45<sup>a</sup>  |
|                      | D2     |              | 64.67 ± 6.69<sup>a</sup>  |
|                      | D3     |              | 48.00 ± 8.50<sup>a</sup>  |
| *L. lactis* subspecies lactis MF480428 | D1     | M            | 58.67 ± 1.67<sup>a</sup>  |
|                      | D2     |              | 50.00 ± 3.00<sup>a</sup>  |
|                      | D3     |              | 50.70 ± 10.3<sup>a</sup>  |
| *E. faecium* MF480431 | D1     | M            | 63.33 ± 6.84<sup>a</sup>  |
|                      | D2     |              | 60.33 ± 3.67<sup>a</sup>  |
|                      | D3     |              | 57.33 ± 1.20<sup>a</sup>  |
| *P. acidilactici* MF480434 | D1    | M            | 58.33 ± 2.67<sup>a</sup>  |
|                      | D2     |              | 50.00 ± 2.89<sup>a</sup>  |
|                      | D3     |              | 48.00 ± 3.61<sup>a</sup>  |
|                      |        | Control (F)  | 57.00 ± 2.00<sup>a</sup>  |
|                      |        |              | 49.67 ± 2.67<sup>a</sup>  |
|                      |        |              | 48.67 ± 3.67<sup>a</sup>  |
| *L. plantarum* MF405176 | D1     | F            | 63.00 ± 5.51<sup>a</sup>  |
|                      | D2     |              | 58.00 ± 11.0<sup>a</sup>  |
|                      | D3     |              | 47.00 ± 4.93<sup>a</sup>  |
| *L. fermentum* MF033346 | D1     | F            | 64.67 ± 9.13<sup>a</sup>  |
|                      | D2     |              | 68.00 ± 6.56<sup>a</sup>  |
|                      | D3     |              | 49.33 ± 0.33<sup>a</sup>  |
| *L. lactis* subspecies lactis MF480428 | D1    | F            | 68.33 ± 9.61<sup>a</sup>  |
|                      | D2     |              | 34.70 ± 13.7<sup>a</sup>  |
|                      | D3     |              | 46.33 ± 5.33<sup>a</sup>  |
| *E. faecium* MF480431 | D1     | F            | 70.67 ± 2.23<sup>a</sup>  |
|                      | D2     |              | 51.33 ± 9.84<sup>a</sup>  |
|                      | D3     |              | 51.67 ± 0.33<sup>a</sup>  |
| *P. acidilactici* MF480434 | D1    | F            | 53.33 ± 2.67<sup>a</sup>  |
|                      | D2     |              | 59.33 ± 3.53<sup>a</sup>  |
|                      | D3     |              | 56.33 ± 6.98<sup>a</sup>  |

Data is expressed as mean ± SEM, n=5. Within a column containing three doses of each probiotic candidate compared to control, mean values superscripted with different letters are significantly different (P < 0.05). D1) Dose 1: 10<sup>6</sup> CFU/ml, D2) Dose 2: 10<sup>9</sup> CFU/ml, D3) Dose 3: 10<sup>12</sup> CFU/ml. Male (M), Female (F). High Density Lipids (HDL), Cholesterol, Triglycerides, Low-Density Lipid (LDL) and Very Low-Density Lipid (VLDL).
Table 3 Liver function of rat blood in acute oral toxicity study

| Probiotic Candidate | Dose | Control (M) | D1 | D2 | D3 |
|---------------------|------|-------------|----|----|----|
| L. plantarum MF405176 | D1   | 0.13 ± 0.00 | 0.08 ± 0.03 | 0.13 ± 0.01 | 0.10 ± 0.01 |
|                     | D2   |             | 0.01 ± 0.01 | 0.03 ± 0.01 | 0.03 ± 0.01 |
|                     | D3   |             | 67.67 ± 3.18 | 74.00 ± 7.57 | 61.67 ± 7.13 |
| L. fermentum MF033346 | D1   | 0.09 ± 0.01 | 0.04 ± 0.02 | 0.10 ± 0.02 | 0.09 ± 0.00 |
|                     | D2   |             | 55.33 ± 6.17 | 50.7 ± 12.0 | 57.67 ± 6.84 |
|                     | D3   |             | 78.33 ± 0.02 | 49.00 ± 7.37 | 62.33 ± 9.60 |
| L. lactis subspecies lactis MF480428 | D1   | 0.14 ± 0.03 | 0.03 ± 0.01 | 0.10 ± 0.01 | 0.13 ± 0.05 |
|                     | D2   |             | 59.00 ± 5.86 | 89.67 ± 5.36 | 80.00 ± 9.07 |
|                     | D3   |             | 70.0 ± 5.01 | 63.33 ± 1.86 | 83.00 ± 11.0 |
| E. faecium MF480431 | D1   | 0.09 ± 0.01 | 0.02 ± 0.01 | 0.11 ± 0.02 | 0.09 ± 0.00 |
|                     | D2   |             | 61.33 ± 8.25 | 71.00 ± 8.50 | 93.67 ± 2.85 |
|                     | D3   |             | 73.33 ± 3.01 | 64.00 ± 22.0 | 75.30 ± 11.1 |
| P. acidilactici MF480434 | D1   | 0.09 ± 0.01 | 0.02 ± 0.00 | 0.12 ± 0.00 | 0.09 ± 0.01 |
|                     | D2   |             | 62.67 ± 8.99 | 64.33 ± 4.91 | 75.67 ± 9.82 |
|                     | D3   |             | 78.67 ± 8.99 | 67.67 ± 4.18 | 72.00 ± 4.73 |
| Control (F) | 0.12 ± 0.01 | 0.01 ± 0.00 | 71.33 ± 2.67 | 55.00 ± 3.00 | <03 ± 0.00 |

Data is expressed as mean ± SEM, n=5 Within a column containing three doses of each probiotic candidate compared to control, mean values superscripted with different letters are significantly different (P < 0.05). D1) Dose 1: 10⁸ CFU/ml, D2) Dose 2: 10⁹ CFU/ml, D3) Dose 3: 10¹⁰ CFU/ml. Male (M), Female (F). ALT (alanine transaminase).
Table 4 Body weight gain of rats during the sub-chronic oral toxicity study

| Probiotic candidate | Control/Dose | Male               | Female          |
|---------------------|--------------|--------------------|-----------------|
|                     |              | Control/Dose       | Male            | Female          |
|                     |              | Control/Dose       | 61.00 ± 10.4    | 52.00 ± 4.08    |
| **L. plantarum MF405176** | D1           | 61.00 ± 9.3        | 50.10 ± 9.0     |
|                     | D2           | 60.20 ± 11.0       | 54.92 ± 9.1     |
|                     | D3           | 62.10 ± 10.0       | 53.30 ± 11.6    |
| **L. fermentum MF033346** | D1           | 61.20 ± 10.5       | 50.10 ± 8.5     |
|                     | D2           | 59.90 ± 12.0       | 53.45 ± 9.1     |
|                     | D3           | 64.50 ± 11.5       | 54.80 ± 10.3    |
| **L. lactis subspecies lactis MF480428** | D1           | 61.10 ± 12.0       | 51.15 ± 11.55   |
|                     | D2           | 61.30 ± 9.5        | 59.08 ± 10.50   |
|                     | D3           | 60.00 ± 8.4        | 56.25 ± 8.56    |
| **E. faecium MF480431** | D1           | 62.20 ± 9.0        | 51.06 ± 9.0     |
|                     | D2           | 66.52 ± 11.0       | 51.18 ± 8.1     |
|                     | D3           | 64.15 ± 9.8        | 54.31 ± 11.0    |
| **P. acidilactici MF480434** | D1           | 64.40 ± 11.2       | 55.55 ± 8.0     |
|                     | D2           | 60.15 ± 12.2       | 48.10 ± 9.7     |
|                     | D3           | 68.10 ± 11.0       | 51.75 ± 5.5     |

Data is expressed as mean ± SEM, n=10. D1) Dose 1: 10^8 CFU/ml, (D2) Dose 2: 10^10 CFU/ml, (D3) Dose 3: 10^12 CFU/ml.
Table 5  Hematology of rat blood in sub-chronic oral toxicity study

| Probiotic Candidate | Dose | Hematological Parameters | Control (F) | Hb (g/dl) | RBC (Million/μl) | HCT/PCV (%) | MCV (fl) | MCH (pg) | WBC (×10⁹/l) | Platelet (×10⁹/l) |
|---------------------|------|--------------------------|-------------|----------|-----------------|--------------|----------|----------|--------------|-----------------|
| L. plantarum        | D1   | F                         | D2          | D3        |                 |              |          |          |              |                 |
| MF405176            |      |                           |             | 12.98 ± 0.32⁵ | 7.54 ± 0.48⁶ | 44.73 ± 2.23⁶ | 59.50 ± 1.05⁶ | 18.00 ± 0.55⁶ | 6.80 ± 1.07⁶ | 1103.5 ± 95.7⁶ |
| L. fermentum        | D1   | M                         | D2          | 13.18 ± 0.55⁵ | 7.88 ± 0.17⁶ | 42.75 ± 1.63⁶ | 54.20 ± 1.10⁶ | 16.73 ± 0.41⁶ | 7.45 ± 2.37⁶ | 1104.8 ± 51.1⁶ |
| MF033346            |      |                           | D3          | 13.53 ± 0.37⁵ | 6.69 ± 0.54⁶ | 44.48 ± 1.98⁶ | 56.13 ± 0.77⁶ | 17.03 ± 0.28⁶ | 6.73 ± 1.60⁶ | 980.30 ± 40.3⁶ |
| L. lactis subsp.    | D1   | M                         | D2          | 13.78 ± 0.37⁵ | 7.94 ± 0.27⁶ | 44.30 ± 1.00⁶ | 56.68 ± 0.58⁶ | 17.75 ± 0.12⁶ | 6.50 ± 1.22⁶ | 918.5 ± 30.6⁶ |
| lactis              |      |                           | D3          | 13.65 ± 0.19⁵ | 7.87 ± 0.08⁶ | 44.45 ± 0.63⁶ | 56.50 ± 0.58⁶ | 17.35 ± 0.27⁶ | 7.55 ± 0.63⁶ | 1086 ± 126⁶ |
| E. faecium          | D1   | M                         | D2          | 16.38 ± 0.28⁵ | 9.91 ± 0.12⁶ | 53.60 ± 0.51⁶ | 54.10 ± 0.82⁶ | 16.96 ± 0.10⁶ | 7.45 ± 1.14⁶ | 1137.5 ± 59.5⁶ |
| MF480431            |      |                           | D3          | 15.38 ± 0.38⁵ | 7.32 ± 1.55⁶ | 44.95 ± 2.22⁶ | 64.03 ± 4.07⁶ | 19.73 ± 8.9⁶ | 7.90 ± 0.8⁶ | 1200.5 ± 27.6⁶ |
| P. acidilactici     | D1   | M                         | D2          | 16.60 ± 0.25⁵ | 8.03 ± 0.31⁶ | 44.10 ± 1.15⁶ | 55.03 ± 1.01⁶ | 17.00 ± 0.35⁶ | 7.25 ± 2.85⁶ | 1016.0 ± 64.9⁶ |
| MF480434            |      |                           | D3          | 14.55 ± 0.35⁵ | 8.31 ± 0.27⁶ | 49.85 ± 1.07⁶ | 64.03 ± 0.74⁶ | 19.53 ± 0.20⁶ | 6.33 ± 1.19⁶ | 1079.8 ± 34.4⁶ |
| L. plantarum        | D1   | F                         | D2          | 12.00 ± 0.62⁵ | 6.74 ± 0.41⁶ | 38.93 ± 2.31⁶ | 57.77 ± 0.45⁶ | 19.38 ± 0.19⁶ | 6.85 ± 0.43⁶ | 1030.0 ± 60.6⁶ |
| MF405176            |      |                           | D3          | 13.23 ± 0.36⁵ | 6.82 ± 0.13⁶ | 40.38 ± 1.45⁶ | 59.13 ± 1.18⁶ | 20.53 ± 0.33⁶ | 6.03 ± 0.23⁶ | 1118.0 ± 27.1⁶ |
| L. fermentum        | D1   | F                         | D2          | 12.15 ± 0.22⁵ | 6.36 ± 0.17⁶ | 38.50 ± 0.70⁶ | 58.85 ± 0.93⁶ | 19.57 ± 0.46⁶ | 6.15 ± 0.42⁶ | 1013.0 ± 24.5⁶ |
| MF033346            |      |                           | D3          | 12.78 ± 0.19⁵ | 7.00 ± 0.15⁶ | 40.15 ± 1.08⁶ | 57.30 ± 0.52⁶ | 18.23 ± 0.13⁶ | 6.83 ± 0.68⁶ | 1070.3 ± 25.2⁶ |
| L. lactis subsp.    | D1   | F                         | D2          | 12.37 ± 0.36⁵ | 7.00 ± 0.08⁶ | 40.58 ± 1.53⁶ | 57.88 ± 1.51⁶ | 17.65 ± 0.32⁶ | 7.28 ± 1.10⁶ | 931.3 ± 78.5⁶ |
| lactis              |      |                           | D3          | 13.18 ± 0.37⁵ | 6.97 ± 0.21⁶ | 42.53 ± 1.15⁶ | 61.10 ± 0.94⁶ | 19.93 ± 0.31⁶ | 5.30 ± 0.53⁶ | 990.3 ± 45.5⁶ |
| E. faecium          | D1   | F                         | D2          | 12.45 ± 0.31⁵ | 6.89 ± 0.17⁶ | 42.73 ± 1.06⁶ | 61.30 ± 0.62⁶ | 19.30 ± 0.11⁶ | 5.98 ± 1.20⁶ | 963.3 ± 49.8⁶ |
| MF480434            |      |                           | D3          | 13.15 ± 0.29⁵ | 7.41 ± 0.11⁶ | 42.53 ± 1.00⁶ | 57.35 ± 0.56⁶ | 17.75 ± 0.22⁶ | 6.45 ± 0.66⁶ | 1059.5 ± 28.7⁶ |
| P. acidilactici     | D1   | F                         | D2          | 12.47 ± 0.28⁵ | 7.12 ± 0.16⁶ | 40.02 ± 0.66⁶ | 56.20 ± 0.48⁶ | 17.52 ± 0.22⁶ | 7.01 ± 0.97⁶ | 1012.5 ± 91.5⁶ |
| MF480434            |      |                           | D3          | 12.83 ± 0.49⁵ | 6.99 ± 0.21⁶ | 44.00 ± 1.57⁶ | 61.03 ± 1.58⁶ | 19.38 ± 0.54⁶ | 6.55 ± 0.82⁶ | 978.8 ± 45.2⁶ |

Data is expressed as mean ± SEM, n=10. Within a column containing three doses of each probiotic candidate compared to control, mean values superscripted with different letters are significantly different (P < 0.05). D1: Dose 1:10⁹ CFU/ml, (D2): Dose 1:10⁸ CFU/ml, (D3): Dose 1:10⁷ CFU/ml. Male (M), Female (F), Hemoglobin (Hb), Erythrocyte count (RBC), Hematocrit/Packed Cell Volume (HCT/PCV), Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin (MCH) and Total leucocyte count (WBC).
### Table 6 Lipid profile of rat blood in sub-chronic oral toxicity study

| Probiotic candidates | Dose | Control / Sex | Lipid profile parameters | Cholesterol (mg/dl) | Triglycerides (mg/dl) | HDL (mg/dl) | LDL (mg/dl) | VLDL (mg/dl) |
|----------------------|------|---------------|---------------------------|---------------------|-----------------------|------------|-----------|-------------|
| *L. plantarum* MF405176 | D1   | M             |                           |                     |                       |            |           |             |
|                      | D2   |               |                           |                     |                       |            |           |             |
|                      | D3   |               |                           |                     |                       |            |           |             |
| *L. fermentum* MF033346 | D1   | M             |                           |                     |                       |            |           |             |
|                      | D2   |               |                           |                     |                       |            |           |             |
|                      | D3   |               |                           |                     |                       |            |           |             |
| *L. lactis* subspecies lactis MF480428 | D1       | M             |                           |                     |                       |            |           |             |
|                      | D2   |               |                           |                     |                       |            |           |             |
|                      | D3   |               |                           |                     |                       |            |           |             |
| *E. faecium* MF480431 | D1   | M             |                           |                     |                       |            |           |             |
|                      | D2   |               |                           |                     |                       |            |           |             |
|                      | D3   |               |                           |                     |                       |            |           |             |
| *P. acidilactici* MF480434 | D1       | M             |                           |                     |                       |            |           |             |
|                      | D2   |               |                           |                     |                       |            |           |             |
|                      | D3   |               |                           |                     |                       |            |           |             |

Data is expressed as mean ± SEM, n=10. Within a column containing three doses of each probiotic candidate compared to control, mean values superscripted with different letters are significantly different (P < 0.05). D1) Dose 1: 10^6 CFU/ml; ([D2]) Dose 2: 10^6 CFU/ml; (D3) Dose 3: 10^6 CFU/ml. Male (M) Female (F). High Density Lipids (HDL), Cholesterol, Triglycerides, Low-Density Lipid (LDL) and Very Low-Density Lipid (VLDL).
Table 7 Liver function of rat blood in sub-chronic oral toxicity study

| Probiotic Candidate | Dose | Liver function parameters |
|---------------------|------|---------------------------|
|                     |      | Total bilirubin (mg/dl) | Direct bilirubin (mg/dl) | ALT (U/L) | Alkaline phosphatase (U/L) | Gamma GT(U/L) |
|                     |      | 0.10 ± 0.01 | 0.05 ± 0.01 | 77.00 ± 1.78 | 83.00 ± 27.9 | <0.3 ± 0.00 |
| L.plantarum MF405176 | D1   | 0.12 ± 0.01 | 0.05 ± 0.01 | 72.75 ± 4.66 | 83.50 ± 31.3 | <0.3 ± 0.00 |
|                     | D2   | 0.12 ± 0.00 | 0.04 ± 0.01 | 68.00 ± 4.95 | 93.80 ± 18.1 | <0.3 ± 0.00 |
|                     | D3   | 0.13 ± 0.02 | 0.05 ± 0.01 | 70.43 ± 3.68 | 117 ± 19.0  | <0.3 ± 0.00 |
| L.fermentum MF033346 | D1   | 0.12 ± 0.20 | 0.04 ± 0.02 | 66.00 ± 8.50 | 89.30 ± 15.9 | <0.3 ± 0.00 |
|                     | D2   | 0.11 ± 0.02 | 0.02 ± 0.00 | 85.50 ± 4.50 | 87.00 ± 4.12 | <0.3 ± 0.00 |
|                     | D3   | 0.13 ± 0.02 | 0.02 ± 0.00 | 74.67 ± 2.79 | 92.00 ± 25.7 | <0.3 ± 0.00 |
| L.lactis subspecies lactis MF480428 | D1   | 0.12 ± 0.01 | 0.05 ± 0.01 | 54.25 ± 1.75 | 84.25 ± 7.12 | <0.3 ± 0.00 |
|                     | D2   | 0.11 ± 0.01 | 0.03 ± 0.00 | 70.00 ± 11.0  | 121.3 ± 10.8 | <0.3 ± 0.00 |
|                     | D3   | 0.11 ± 0.01 | 0.03 ± 0.01 | 81.30 ± 5.35  | 128.1 ± 21.0 | <0.3 ± 0.00 |
| E.faecium MF480431 | D1   | 0.11 ± 0.02 | 0.05 ± 0.01 | 31.25 ± 1.75 | 200.0 ± 24.3 | <0.3 ± 0.00 |
|                     | D2   | 0.11 ± 0.01 | 0.05 ± 0.00 | 44.00 ± 2.83 | 139.7 ± 8.52 | <0.3 ± 0.00 |
|                     | D3   | 0.08 ± 0.02 | 0.05 ± 0.00 | 74.33 ± 8.27 | 159.2 ± 27.1 | <0.3 ± 0.00 |
| P.acidilactici MF480434 | D1   | 0.12 ± 0.01 | 0.03 ± 0.02 | 59.25 ± 9.41 | 160.8 ± 23.0 | <0.3 ± 0.00 |
|                     | D2   | 0.10 ± 0.01 | 0.05 ± 0.00 | 82.00 ± 5.83 | 172.8 ± 27.0 | <0.3 ± 0.00 |
|                     | D3   | 0.07 ± 0.02 | 0.05 ± 0.00 | 84.63 ± 1.62 | 130.0 ± 15.6 | <0.3 ± 0.00 |
| Control (F) |      | 0.10 ± 0.01 | 0.05 ± 0.01 | 57.00 ± 1.70 | 78.0 ± 21.4 | <0.3 ± 0.00 |
| L.plantarum MF405176 | D1   | 0.12 ± 0.03 | 0.05 ± 0.00 | 65.25 ± 7.38 | 74.80 ± 25.6 | <0.3 ± 0.00 |
|                     | D2   | 0.09 ± 0.00 | 0.04 ± 0.02 | 45.25 ± 4.31 | 62.00 ± 10.4 | <0.3 ± 0.00 |
|                     | D3   | 0.12 ± 0.04 | 0.04 ± 0.01 | 66.50 ± 4.56 | 74.80 ± 11.7 | <0.3 ± 0.00 |
| L.fermentum MF033346 | D1   | 0.11 ± 0.12 | 0.05 ± 0.01 | 77.50 ± 3.20 | 71.50 ± 41.3 | <0.3 ± 0.00 |
|                     | D2   | 0.09 ± 0.01 | 0.03 ± 0.00 | 40.75 ± 9.81 | 54.75 ± 2.29 | <0.3 ± 0.00 |
|                     | D3   | 0.06 ± 0.03 | 0.04 ± 0.00 | 67.50 ± 1.19 | 73.50 ± 20.6 | <0.3 ± 0.00 |
| L.lactis subspecies lactis MF480428 | D1   | 0.12 ± 0.01 | 0.04 ± 0.00 | 78.00 ± 17.9 | 71.50 ± 60.3 | <0.3 ± 0.00 |
|                     | D2   | 0.13 ± 0.02 | 0.10 ± 0.01 | 85.00 ± 28.9 | 75.50 ± 27.1 | <0.3 ± 0.00 |
|                     | D3   | 0.11 ± 0.02 | 0.04 ± 0.01 | 87.50 ± 10.2 | 75.50 ± 45.2 | <0.3 ± 0.00 |
| E.faecium MF480431 | D1   | 0.13 ± 0.01 | 0.05 ± 0.00 | 58.50 ± 2.72 | 78.00 ± 15.1 | <0.3 ± 0.00 |
|                     | D2   | 0.13 ± 0.01 | 0.01 ± 0.00 | 64.00 ± 10.7 | 78.50 ± 65.2 | <0.3 ± 0.00 |
|                     | D3   | 0.07 ± 0.03 | 0.01 ± 0.00 | 54.00 ± 2.04 | 74.25 ± 5.75 | <0.3 ± 0.00 |
| P.acidilactici MF480434 | D1   | 0.11 ± 0.00 | 0.04 ± 0.01 | 41.75 ± 5.45 | 64.80 ± 10.8 | <0.3 ± 0.00 |
|                     | D2   | 0.10 ± 0.01 | 0.02 ± 0.01 | 72.50 ± 5.04 | 71.50 ± 15.4 | <0.3 ± 0.00 |
|                     | D3   | 0.06 ± 0.03 | 0.01 ± 0.00 | 84.50 ± 2.60 | 56.50 ± 0.87 | <0.3 ± 0.00 |

Data is expressed as mean ± SEM, n=10. Within a column containing three doses of each probiotic candidate compared to control, mean values superscripted with different letters are significantly different (P < 0.05). D1) Dose 1: 1.0×CFU/ml (D2) Dose 2: 10×CFU/ml, (D3) Dose 3: 100×CFU/ml.

4. Discussion

Consumer demand for new probiotics with potential applications in alternative therapy, especially in treating several non-communicable diseases is increasing (Shokryazdan et al., 2017). With the increasing health awareness among consumers, attraction towards healthy probiotic functional food is growing. Factors such as milk protein allergy, lactose intolerance, high fat content and drift towards vegetarianism are the major limitations associated with dairy based probiotics. Hence research is being continued in developing alternate solutions to dairy based probiotic products and preference for non-dairy based probiotic products especially using cereals as major substrate is a choice attraction (Divisekera et al., 2019b). Absence of difference in terms of health benefits irrespective of the source of probiotic isolation (dairy, non-dairy) revealed in literature further supports this emerging trend (Kumar et al., 2015). Assessment of safety attributes is necessary before considering efficacy proven new probiotic strains in food and pharmaceutical applications.

Five probiotic candidate under study, Lactobacillus plantarum MF405176, Lactobacillus fermentum MF033346, Lactococcus
**Acknowledgments**

Financial assistance by the Indo-Sri Lanka Inter-Governmental Science and Technology Cooperation Programme Grant Number: I-P-110.

Centre for Science and Technology of the Non-Aligned and Other Developing Countries for awarding joint NAM-IJCCBS Postgraduate Research Fellowship for Divisendra Mudyanesangle Aswanda Devanmini Divisikera.

Dr. Syed Mehmood Hasan, Professor of Pathology, Sindh Medical College, Jinnah Sindh Medical University, Pakistan for providing technical assistance in histopathological examinations.

**Declaration of interest**

The authors have no conflicts of interest.

**References**

1. Abotsi, W.K.M., Ainoson, G.K. & Qyasi, E.B. (2011). Acute and Subacute Toxicity Studies of the Ethanolic Extract of the Aerial Parts of Hilleria Latifolia (Lam.) H. Walt. (Phytolaccaceae) in Rodents. West African Journal of Pharmacy, 22, 7–35.

2. Conway, P.L. (1996). Selection criteria for probiotic microorganisms. Asia Pacific Journal of Clinical Nutrition, 5, 10–14.

3. Denkova, R., Goranova, B., Teneva, D., Denkova, Z. & Kostov, G. (2017) Antimicrobial activity of probiotic microorganisms: mechanisms of interaction and methods of examination. 1st ed Mendez-Vilas A.

4. Divisikera, D.W.D., Samarasekera J.K.R.R., Hettiarachchi C., Goonaratne J., & Gopalakrishnan S. (2019) Sri Lankan finger millet (Eleusine coracana) Variety ‘Ravanna’ as Potential Probiotic source. In: Evolving Industrial Biotechnology in Developing Countries, Ogbadu, L, Ogbadu, G and Mahamadi, C Ed. NAM S&T Centre publications, New Delhi, 167–183. ISBN:79898892016.

5. Divisikera, D.W.D., Samarasekera J.K.R.R., Hettiarachchi C., Goonaratne, J., Gopalakrishnan, S. & Wabah, A.T (2019) Lactic acid bacteria isolated from fermented flour of finger millet, its probiotic attributes and bioactive properties. Annals of Microbiology, 69, 79–92. [https://dx.doi.org/10.1007/s13213-018-1399-y](https://dx.doi.org/10.1007/s13213-018-1399-y)

6. Ducheneau, C.T., Jones, M.L., Shah, D., Jain, P., Saha, S. & Prakash, S. (2014) Cholesterol Assimilation by Lactobacillus salivarius CECT5713. International Journal of Food Science and Nutrition, 65, 266–270. [https://dx.doi.org/10.1080/09639908.2014.924246](https://dx.doi.org/10.1080/09639908.2014.924246)

7. FAO/WHO Guidelines for the Evaluation of Probiotics in Food 2002. Available from: [www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf](http://www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf). Accessed November 10, 2020.

8. Fenster, K., Freeburg, B., Holland, C., Wong, C., Laursen, R.R. & Ouwehand, A.C. (2019). The Production and Delivery of Probiotics: A Review of a Practical Approach. Microorganisms, 8, 1–7. [https://doi.org/10.3390/microorganisms7030083](https://doi.org/10.3390/microorganisms7030083)

9. Gionchetti, P., Rizzello, F., Morcelli, C., Poggelli, G., Tambasco, R., Calabrese, C., Brigidi, P., Vitali, R., Sfarafinir, C. & Campieri, M. (2007) High-dose probiotics for the treatment of active pouchitis. Disease of the Colon and Rectum, 50, 2075–2082.

10. Iannaccone, P.M. & Jacob, H.J. (2009). Rats. Disease Models and Mechanisms, 2, 206–210. [https://doi.org/10.1242/dmm.002723](https://doi.org/10.1242/dmm.002723)

11. Kumar, V.B., Vijayendra, S.V.N. & Reddy, G.V.S. (2015). Trends in dairy and non-dairy probiotic products - a review. Journal of Food Science and Technology, 52, 6112–6124. [https://doi.org/10.1007/s13197-015-1795-2](https://doi.org/10.1007/s13197-015-1795-2)

12. Lara-Villoslada, F., Sierra, S., Diz-Rupero, M.P., Olivares, M. & Xaus, J (2007). Safety Assessment of the Human Milk-Isolated Probiotic Lactobacillus salivarius CECT5713. Journal of Dairy Science, 90 (8), 3583–3589. [https://doi.org/10.3168/jds.2006-6685](https://doi.org/10.3168/jds.2006-6685)

13. Motevaseli, E., Dianatpour, A. & Ghafari, S.F. (2017). The Role of Probiotics in Cancer Treatment: Emphasis on their In Vivo and In Vitro Anti-metastatic Effects. International Journal of Molecular and Cellular Medicine, 66–76. [https://doi.org/10.22088/acadpub.BUMS.6.2.1](https://doi.org/10.22088/acadpub.BUMS.6.2.1)

14. Quinto, E.J., Jimenez, P., Caro, I., Tejero, J., Mateo, J. & Girbes, T. (2014) Probiotic Lactic Acid Bacteria: A Review. Food Science and Nutrition, 5, 1765-1775. [https://doi.org/10.4236/fsn.2014.518190](https://doi.org/10.4236/fsn.2014.518190)
15. Sert, P.N., Ahluwalia, A., Alam, S., Avey, M.T., Baker, M., Browne, W.J., et al (2020). Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0. PLoS Biol 18(7): http://dx.doi.org/10.1371/journal.pbio.3000411

16. Shokryazdan, P., Jahromi, F.M., Liang, J.B., Kalavathy, R., Sieo, C.C. & Ho, Y.W. (2017). Effects of a Lactobacillus salivarius mixture on performance, intestinal health and serum lipids of broiler chickens. PLOS ONE 11, https://doi.org/10.1371/journal.pbio.3000411

17. Steffen, E. K. & R. D. Berg. (1983). Relationship between caecal population levels of indigenous bacteria and translocation to the mesenteric lymph nodes. Infestation and Immunity, 39:1252–1259. https://doi.org/10.1128/iai.39.3.1252-1259.1983

18. Tripathi, M.K. & Giri, S.K. (2014). Probiotic functional foods: Survival of probiotics during processing and storage. Journal of Functional Foods, 9, 225-24. https://doi.org/10.1016/j.jff.2014.04.030

19. Wang, Y., Wu, Y., Wang, Y., Xu, H., Mei, X., Yu, D., Wang, Y. & Li, W. (2017). Antioxidant Properties of Probiotic Bacteria. Nutrients, 9, https://doi.org/10.3390/nu9050521

20. Zhou, J.S., Shu, Q., Rutherford, K.J., Prasad, J., Gopal, P.K. & Gill, H.S. (2000). Acute oral toxicity and bacterial translocation studies on potentially probiotic strains of lactic acid bacteria. Food Chemistry and Toxicology, 38, 153-161. https://doi.org/10.1016/S0278-6915(99)00154-4

21. Zielinska, D., Oldak, A., Rzepkowska, A. & Zielinski, K. (2018). Advances in Biotechnology for Food Industry. Ed. Holban A & Grumezescu, A.M. eBook ISBN: 978012811495